Literature DB >> 7790950

A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

S Minoshima1, K A Frey, R A Koeppe, N L Foster, D E Kuhl.   

Abstract

UNLABELLED: To improve the diagnostic performance of PET as an aid in evaluating patients suspected of having Alzheimer's disease, we developed a fully automated method which generates comprehensive image presentations and objective diagnostic indices.
METHODS: Fluorine-18-fluorodeoxyglucose PET image sets were collected from 37 patients with probable Alzheimer's disease (including questionable and mild dementia), 22 normal subjects and 5 patients with cerebrovascular disease. Following stereotactic anatomic standardization, metabolic activity on an individual's PET image set was extracted to a set of predefined surface pixels (three-dimensional stereotactic surface projection, 3D-SSP), which was used in the subsequent analysis. A normal database was created by averaging extracted datasets of the normal subjects. Patients' datasets were compared individually with the normal database by calculating a Z-score on a pixel-by-pixel basis and were displayed in 3D-SSP views for visual inspections. Diagnostic indices were then generated based on averaged Z-scores for the association cortices.
RESULTS: Patterns and severities of metabolic reduction in patients with probable Alzheimer's disease were seen in the standard 3D-SSP views of extracted raw data and statistical Z-scores. When discriminating patients with probable Alzheimer's disease from normal subjects, diagnostic indices of the parietal association cortex and unilaterally averaged parietal-temporal-frontal cortex showed sensitivities of 95% and 97%, respectively, with a specificity of 100%. Neither index yielded false-positive results for cerebrovascular disease.
CONCLUSION: 3D-SSP enables quantitative data extraction and reliable localization of metabolic abnormalities by means of stereotactic coordinates. The proposed method is a promising approach for interpreting functional brain PET scans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790950

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  267 in total

1.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome.

Authors:  T Siessmeier; W A Nix; J Hardt; M Schreckenberger; U T Egle; P Bartenstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

3.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

4.  Cerebral single photon emission computer tomography in thalamic lacunar infarction presenting with amnesia.

Authors:  Kiyotaka Nakamagoe; Akira Tamaoka
Journal:  BMJ Case Rep       Date:  2009-09-28

5.  Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

Authors:  José V Pardo; Joel T Lee; Michael A Kuskowski; Kristin R Munch; John V Carlis; Sohail A Sheikh; Christa Surerus; Scott M Lewis; J Riley McCarten; Howard Fink; Susan McPherson; Hemant H Shah; Susan Rottunda; Maurice W Dysken
Journal:  Alzheimers Dement       Date:  2010-05-06       Impact factor: 21.566

6.  Reversible brain hypometabolism associated with central nervous system systemic lupus erythematosus.

Authors:  Jukka Kemppainen; Sami Kajander; Timo Yli-Kerttula; Laura Airas; Marko Seppänen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

7.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

9.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

10.  Adaptive template generation for amyloid PET using a deep learning approach.

Authors:  Seung Kwan Kang; Seongho Seo; Seong A Shin; Min Soo Byun; Dong Young Lee; Yu Kyeong Kim; Dong Soo Lee; Jae Sung Lee
Journal:  Hum Brain Mapp       Date:  2018-05-11       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.